Publications

Publications

Filter Results: (11) Arrow Down

Show Results For

Page 1 of 11 Results
  • August 2013 (Revised October 2013)
  • Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Related
  • January 2014
  • Teaching Plan

MedImmune Ventures

By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details
Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States
Related
  • Video

Dr. Silvia Gold

Dr. Silvia Gold, President of the Mundo Sano Foundation and co-founder of Grupo Insud, outlines her company’s experience with prior public health crises such as the H1N1 outbreak, which allowed them to rapidly license and start producing materials for the AstraZeneca... View Details
  • September 2014 (Revised February 2015)
  • Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Related
  • Web

Recruiting Partners - Health Care

Ascensia Diabetes Care Ask Big Questions AstraZeneca athenahealth ATI Physical Therapy | Advent International Portfolio Company Atlantic Council Augmedix Inc. Autism Spectrum Therapies Avenue Pacific AVIA Axcella Health B Bain & Co. Bank... View Details
  • 31 Jan 2014
  • News

Body, Heal Thyself

Chien and Derrick Rossi, published a paper in the journal Nature Biotechnology that showed mRNA Therapeutics was capable of stimulating blood vessel growth, repairing damaged heart tissue, and helping a mouse through myocardial infarction. In March of 2013, View Details
Keywords: Maureen Harmon; biotech; Health, Social Assistance; Scientific Research and Development Services
  • 25 Apr 2014
  • News

A revolution in healing

formerly was CEO of bioMérieux. He joined the company in 2011 after seeing impressive data indicating Moderna had found an entirely new way to treat rare diseases and cancer—using technology that was inexpensive to produce. The company is winning some big supporters.... View Details
  • 25 May 2016
  • Research & Ideas

How Consumers and Businesses are Reshaping Public Health

commercialization of important new drugs to the detriment of consumers. Interestingly, though, at public hearings, the AstraZeneca chief executive championed the interests of patients in opposing the proposed merger. Consumers worldwide... View Details
Keywords: by John A. Quelch; Health
  • 24 Sep 2020
  • News

The Race for a Vaccine

to enroll 30,000 people in the United States, and two large pharmaceutical companies: AstraZeneca and the University of Oxford had a vaccine based on a chimpanzee adenovirus in Phase 3 trials in Brazil and South Africa, while US-based... View Details
Keywords: April White; COVID-19; Scientific Research and Development Services
  • 14 Dec 2020
  • Research & Ideas

What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?

saying; “Look, everyone should understand that this is risky.” And yet, as I mentioned above, I don’t think this is going to happen. This AstraZeneca hiccup isn’t going to be the last one. I can all but assure you of that. Once we start... View Details
Keywords: by Danielle Kost; Pharmaceutical; Health
  • 28 Oct 2014
  • First Look

First Look: October 28

Business School Case 515-007 Pfizer and AstraZeneca: Marketing an Acquisition (A) In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for... View Details
Keywords: Carmen Nobel